SYRE

Spyre Therapeutics, Inc. is a clinical-stage biotechnology company, which is engaged in creating inflammatory bowel disease (IBD) and other immune-mediated disease products by combining antibody engineering, rational therapeutic combinations and precision medicine approaches. Its pipeline includes investigational extended half-life antibodies targeting a4b7, TL1A, and IL-23. Its pipeline programs include SPY003, SPY004, SPY130, SPY230, SPY002, SPY001, and SPY120. Its advanced product candidate, SPY001, is a fully human monoclonal immunoglobulin G1 antibody designed to bind selectively to the a4b7 integrin being developed for the treatment of IBD. Its co-lead program, SPY002, has nominated two fully human mAb candidates designed to bind to tumor necrosis factor-like ligand 1A (TL1A), both of which are in preclinical development for the treatment of IBD. SPY003 is a preclinical-stage program designed to bind to Interleukin 23 (IL-23) and incorporates half-life extending modifications.

Wall Street analysts forecast SYRE stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for SYRE is 54.00 USD with a low forecast of 43.00 USD and a high forecast of 70.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Spyre Therapeutics Inc revenue for the last quarter amounts to 0.00 USD, decreased % YoY.

Spyre Therapeutics Inc. EPS for the last quarter amounts to -0.19 USD, decreased -86.03 % YoY.

Spyre Therapeutics Inc (SYRE) has 65 emplpoyees as of December 15 2025.

Today SYRE has the market capitalization of 2.61B USD.